Correlation Between Immunovant and Monte Rosa

Can any of the company-specific risk be diversified away by investing in both Immunovant and Monte Rosa at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunovant and Monte Rosa into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immunovant and Monte Rosa Therapeutics, you can compare the effects of market volatilities on Immunovant and Monte Rosa and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunovant with a short position of Monte Rosa. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunovant and Monte Rosa.

Diversification Opportunities for Immunovant and Monte Rosa

-0.2

Correlation Coefficient

Immunovant  Monte Rosa

Good diversification

The 3 months correlation between Immunovant and Monte is -0.2. Overlapping area represents the amount of risk that can be diversified away by holding Immunovant and Monte Rosa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monte Rosa Therapeutics and Immunovant is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunovant are associated (or correlated) with Monte Rosa. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monte Rosa Therapeutics has no effect on the direction of Immunovant i.e., Immunovant and Monte Rosa go up and down completely randomly.

Pair Corralation between Immunovant and Monte Rosa

Given the investment horizon of 90 days Immunovant is expected to generate 1.09 times less return on investment than Monte Rosa. But when comparing it to its historical volatility, Immunovant is 1.34 times less risky than Monte Rosa. It trades about 0.04 of its potential returns per unit of risk. Monte Rosa Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  879.00  in Monte Rosa Therapeutics on September 2, 2024 and sell it today you would earn a total of  157.00  from holding Monte Rosa Therapeutics or generate 17.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Immunovant  vs.  Monte Rosa Therapeutics

Immunovant

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Immunovant is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Monte Rosa Therapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Immunovant and Monte Rosa

The main advantage of trading using opposite Immunovant and Monte Rosa positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunovant position performs unexpectedly, Monte Rosa can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will offset losses from the drop in Monte Rosa's long position.

The idea behind Immunovant and Monte Rosa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.